scholarly journals Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea

2019 ◽  
Vol 8 (3) ◽  
pp. 27-27
Author(s):  
Seock-Ah Im ◽  
Dae-Won Lee ◽  
Ryungwoo Kang ◽  
Jee Hyun Kim ◽  
Dong-Wan Kim ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
University Hospital ◽  
Asia Pacific ◽  
Pacific Region ◽  
Asia Pacific Region ◽  
Oncology Clinical Trial ◽  
National University ◽  
Seoul National University ◽  
Oncology Drug Development

scholarly journals Pediatric Clinical Trials: Current Scenario in the Asia Pacific Region

2013 ◽  
pp. 47 ◽  
Author(s):  
Lisa Marie Saldanha ◽  
Saumya Nayak ◽  
Adeline Sng ◽  
Long ◽  
Elisabeth Schrader ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Asia Pacific ◽  
Pacific Region ◽  
Asia Pacific Region ◽  
Current Scenario

Clinical trials and public trust: the geographical shift to the Asia-Pacific region

2009 ◽  
Vol 12 (3) ◽  
pp. 186-191 ◽  
Author(s):  
Karina D. TORRALBA ◽  
Nasim A. KHAN ◽  
Francisco P. QUISMORIO
Keyword(s):  
Clinical Trials ◽  
Public Trust ◽  
Asia Pacific ◽  
Pacific Region ◽  
Asia Pacific Region

scholarly journals The Safety of Dengvaxia and Should Hospitalization be an Outcome for its Clinical Trial?

2018 ◽  
Vol 1 (1) ◽  
pp. 01-02
Author(s):  
Godofreda Dalmacion
Keyword(s):  
Clinical Trial ◽  
The Philippines ◽  
Asia Pacific ◽  
Efficacy Rate ◽  
Pacific Region ◽  
Efficacy And Safety ◽  
Asia Pacific Region ◽  
Efficacy Trial ◽  
Mass Immunization

The uncertainties on the efficacy and safety of Dengvaxia continue to haunt doctors, parents, and lawmakers alike in the Philippines. After the mass immunization of about 850,000 children with Dengvaxia, there has been a continuing report of deaths, unofficially 29 to date among those who received the vaccine between 2016-2017. Countries in the Asia Pacific region, including the Philippines, were one of the sites for the Dengvaxia Clinical Trial. In 2014, the Efficacy Trial of Dengvaxia covering the period after completion of the 3 doses up to the 28th day was published by Capeding, et al. An overall efficacy rate of 56.5% was reported but it can be misleading since the efficacy rates for each serotype varied widely. The uncertainties on the efficacy and safety of Dengvaxia continue to haunt doctors, parents, and lawmakers alike in the Philippines. After the mass immunization of about 850,000 children with Dengvaxia, there has been a continuing report of deaths, unofficially 29 to date among those who received the vaccine between 2016-2017. Countries in the Asia Pacific region, including the Philippines, were one of the sites for the Dengvaxia Clinical Trial. In 2014, the Efficacy Trial of Dengvaxia covering the period after completion of the 3 doses up to the 28th day was published by Capeding, et al. An overall efficacy rate of 56.5% was reported but it can be misleading since the efficacy rates for each serotype varied widely. The uncertainties on the efficacy and safety of Dengvaxia continue to haunt doctors, parents, and lawmakers alike in the Philippines. After the mass immunization of about 850,000 children with Dengvaxia, there has been a continuing report of deaths, unofficially 29 to date among those who received the vaccine between 2016-2017. Countries in the Asia Pacific region, including the Philippines, were one of the sites for the Dengvaxia Clinical Trial. In 2014, the Efficacy Trial of Dengvaxia covering the period after completion of the 3 doses up to the 28th day was published by Capeding, et al. An overall efficacy rate of 56.5% was reported but it can be misleading since the efficacy rates for each serotype varied widely.

Review of Counseling in the Asia-Pacific Region.

1995 ◽  
Vol 40 (4) ◽  
pp. 383-384
Author(s):  
Terri Gullickson
Keyword(s):  
Asia Pacific ◽  
Pacific Region ◽  
Asia Pacific Region
Sign in / Sign up

Export Citation Format

Share Document